After more than 2 years of relentless campaigning, Enhertu has now been approved for use on the NHS in England for people with HER2-low metastatic breast cancer.
Enhertu was rejected for use on the NHS in England in 2024, but thanks to sustained pressure from supporters like you, the life-extending treatment will now be available to patients in England.
Wales and Northern Ireland usually adopt drug decisions made in England, so we now need both nations to urgently make sure Enhertu is available on the NHS there too, to bring the rest of the UK in line with Scotland, which already approved the drug in 2023.
A huge thank you to everyone who signed our petition! This drug will give thousands the hope of more time with their loved ones.
This victory is a brilliant example of what we can achieve together. We really do have the power to make a difference for people affected by breast cancer.
To find out more about the campaign and what comes next please sign-up to receive updates or visit our website to read our latest news.